en · de · es · fr · pt
aod-9604-notes.peptides7250.com › Info › Background And Molecular Identity — Practical Notes

Background And Molecular Identity — Practical Notes

By Editorial Desk · published 2025-09-14 · last reviewed 2025-10-21 · Info

AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2025-10-21. Anything still debated is marked as such rather than presented as settled.

Background and Molecular Identity

AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.

The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.

Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.

Research and Regulatory Status

Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.

Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.

AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.

Aod-9604 at a glance

PropertyValueNotes
Molecular classSynthetic peptideBased on the C-terminal region of human growth hormone.
Amino acid length16 residuesOften described as hGH fragment 176-191.
AppearanceLyophilized powderTypically white to off-white; exact appearance depends on grade.
SolubilitySoluble in waterAqueous solubility depends on pH, ionic strength, and preparation.
Typical storage-20 °C or lowerLyophilized peptide is usually kept cold and dry; solutions may require freezing.

Notes from published material

the producer phase of a military supply extends from determination of procurement schedules to acceptance of finished supplies by the military services the consumer phase of a military supply extends from receipt of finished supplies by the military services, through issue for use or consumption. A supply chain is a set of linked activities associated with providing material from a raw material stage to an end user as a finished good. Supply control is the process by which an item of supply is controlled within the supply system, including requisitioning, receipt, storage, stock control, shipment, disposition, identification, and accounting. A supply point is a location where supplies, services and materials are located and issued. As a single moving entity, a supply point location is temporary and mobile, normally being occupied for up to 72 hours. Sub-suppliers are those suppliers who provide materials to other suppliers within the supply chain. In other supply chain management contexts they are referred to by tier, second-tier suppliers serving first-tier suppliers, etc. The European Union refers to sub-suppliers in its objective to improve cross-border market access in the defence sector.

in military personnel exposed to high radiation, (during accidents at nuclear reactors), or to combat the action of toxic substances (including organophosphate compounds), combat traumas, as well as to prevent acute respiratory infections and flu. They were also used to treat laser retinal lesions in experimental animals exposed to a combat laser. All other peptide preparations, (natural and synthetic) are at different stages of studying in patients with different diseases. Among the important advantages of all designed peptide preparations is that they lack any toxic, allergic or adverse effects, this has been proven both in experimental and clinical studies. The main objective of studies for the recent decade was fundamental research devoted to the role that small peptides play in the evolution and development of living matter. It was crucial for understanding the mechanism of the action of peptides and evidencing their safety and effectiveness, whilst designing new medicinal preparations, dietary supplements, cosmetics and veterinary preparations.

For example, if the desired analyte has a high amount of acidity, it would be logical to choose a matrix with a high amount of basicity to avoid competition and facilitate the formation of an ion. The pH of the matrix can also be used to select what sample you want to obtain spectra for. For example, in the case of proteins, a very acidic pH can show very little of the peptide components, but can show very good signal for those components that are larger. If the pH is increased towards a more basic pH, then smaller components become easier to see.

=== In prokaryotes === In prokaryotes a small 30S ribosomal subunit contains the 16S ribosomal RNA. The large 50S ribosomal subunit contains two rRNA species (the 5S and 23S ribosomal RNAs). Therefore it can be deduced that in both bacteria and archaea there is one rRNA gene that codes for all three rRNA types :16S, 23S and 5S. Bacterial 16S ribosomal RNA, 23S ribosomal RNA, and 5S rRNA genes are typically organized as a co-transcribed operon. As shown by the image in this section, there is an internal transcribed spacer between 16S and 23S rRNA genes. There may be one or more copies of the operon dispersed in the genome (for example, Escherichia coli has seven). Typically in bacteria there are between one and fifteen copies. Archaea contains either a single rRNA gene operon or up to four copies of the same operon. The 3' end of the 16S ribosomal RNA (in a ribosome) recognizes a sequence on the 5' end of mRNA called the Shine-Dalgarno sequence.

Sources: en.wikipedia.org

Related pages on this site

Background from the literature

== Economic impact == Migraines are a significant source of both medical costs and lost productivity. It has been estimated that migraine is the most costly headache disorder in the European Community, costing €50–111 billion per year in 2012. Most of the costs were due to lost work. As of 2017, in the United States, total costs were estimated at US$78 billion, with the cost per person multiple times bigger for those with chronic migraines. In those who do attend work during a migraine attack, effectiveness is decreased by around a third. Negative effects also frequently occur for a person's family.

Extreme exercise can make capillaries vulnerable, with a breaking point similar to that of collagen. Capillary permeability can be increased by the release of certain cytokines, anaphylatoxins, or other mediators (such as leukotrienes, prostaglandins, histamine, bradykinin, etc.) highly influenced by the immune system.

Double dilution method can be designed such that the isotopic composition of the two blends, A+B and A*+B, is identical, i.e., RAB = RA*B. This condition of exact-matching double isotope dilution simplifies the above equation significantly:

== Evidence-based medicine == Evidence-based medicine is defined as deploying the best current scientific evidence that is available to give the best treatment and make the best decision effectively and efficiently. Clinical guidelines are developed based on scientific evidence; for example, the ACC/AHA guidelines (for cardiovascular diseases), the GOLD guidelines (for chronic obstructive pulmonary disease), the GINA guidelines (for asthma), etc. They convert and classify the evidence using a systematic method, aiming to provide care with quality. The guidelines cannot substitute clinical judgment, as they cannot meet all the circumstances. Healthcare professionals can use the clinical guidelines as references or evidence to support their clinical judgement when prescribing therapy to patients. Example: Clinical Guideline for controlling blood pressure (hypertension) If there is an Asian male patient who is 40 years old and has recently been diagnosed with high blood pressure (with a blood pressure of 140/90) and without any other chronic diseases (comorbidities), such as type-2 diabetes, gout, benign prostatic hyperplasia, etc. His estimated 10-year risk of cardiovascular disease is 15%. According to the NICE 2019 Hypertension guideline, the healthcare professional can consider starting anti-hypertensive therapy after a discussion with the patient. The first-line therapy will be either an Angiotensin Converting Enzyme Inhibitor (ACEi) or an Angiotensin receptor blocker (ARB) (if the patient cannot tolerate ACEi).

As a small open economy, Denmark is very dependent on its foreign trade. In 2017, the value of total exports of goods and services made up 55% of GDP, whereas the value of total imports amounted to 47% of GDP. Trade in goods made up slightly more than 60% of both exports and imports, and trade in services the remaining close to 40%. Machinery, chemicals and related products like medicine and agricultural products were the largest groups of export goods in 2017. Service exports were dominated by freight sea transport services from the Danish merchant navy. Most of Denmark's most important trading partners are neighbouring countries. The five main importers of Danish goods and services in 2017 were Germany, Sweden, United Kingdom, United States and Norway. The five countries from which Denmark imported most goods and services in 2017 were Germany, Sweden, the Netherlands, China and United Kingdom. After having almost consistently an external balance of payments current account deficit since the beginning of the 1960s, Denmark has maintained a surplus on its BOP current account for every year since 1990, with the single exception of 1998. In 2017, the current account surplus amounted to approximately 8% of GDP. Consequently, Denmark has changed from a net debtor to a net creditor country. By 1 July 2018, the net foreign wealth or net international investment position of Denmark was equal to 64.6% of GDP, Denmark thus having the largest net foreign wealth relative to GDP of any EU country.

Sources: en.wikipedia.org

Reference notes

In column chromatography, the column contains a packed column of solid particles, finely ground powders, or gels. This is called the stationary phase or adsorbent. It is most often made of silica gel or alumina. Cellulose powder has often been used in the past. A wide range of stationary phases are available in order to different forms of column chromatographies: ion exchange chromatography, reversed-phase chromatography (RP), affinity chromatography or expanded bed adsorption (EBA). The solid phase may be microporous for an increased surface, though EBA uses a fluidized bed. In general, one should use much more stationary phase than the analyte mixture. For silica column chromatography in particular, for each gram of dry mass of the analyte mixture, there should be 20 to 100 grams of the stationary phase. Using more silica would increase the resolving power of the chromatography, but also make it slower.

=== Mutualists === Certain bacteria form close spatial associations that are essential for their survival. One such mutualistic association, called interspecies hydrogen transfer, occurs between clusters of anaerobic bacteria that consume organic acids, such as butyric acid or propionic acid, and produce hydrogen, and methanogenic archaea that consume hydrogen. Without the archaea, the bacteria in this association would be unable to continuously consume the organic acids, as this reaction produces hydrogen that would accumulate in their surroundings. Only the intimate association with the hydrogen-consuming archaea keeps the hydrogen concentration low enough to allow the bacteria to grow.

Brominated flame retardants represent a commodity of growing importance, and make up the largest commercial use of bromine. When the brominated material burns, the flame retardant produces hydrobromic acid which interferes in the radical chain reaction of the oxidation reaction of the fire. The mechanism is that the highly reactive hydrogen radicals, oxygen radicals, and hydroxyl radicals react with hydrobromic acid to form less reactive bromine radicals (i.e., free bromine atoms). Bromine atoms may also react directly with other radicals to help terminate the free radical chain-reactions that characterise combustion. To make brominated polymers and plastics, bromine-containing compounds can be incorporated into the polymer during polymerisation. One method is to include a relatively small amount of brominated monomer during the polymerisation process. For example, vinyl bromide can be used in the production of polyethylene, polyvinyl chloride or polypropylene. Specific highly brominated molecules can also be added that participate in the polymerisation process. For example, tetrabromobisphenol A can be added to polyesters or epoxy resins, where it becomes part of the polymer. Epoxies used in printed circuit boards are normally made from such flame retardant resins, indicated by the FR in the abbreviation of the products (FR-4 and FR-2). In some cases, the bromine-containing compound may be added after polymerisation. For example, decabromodiphenyl ether can be added to the final polymers.

Tertiary structure refers to the three-dimensional structure created by a single protein molecule (a single polypeptide chain). It may include one or several domains. The α-helices and β-pleated-sheets are folded into a compact globular structure. The folding is driven by the non-specific hydrophobic interactions, the burial of hydrophobic residues from water, but the structure is stable only when the parts of a protein domain are locked into place by specific tertiary interactions, such as salt bridges, hydrogen bonds, and the tight packing of side chains and disulfide bonds. The disulfide bonds are extremely rare in cytosolic proteins, since the cytosol (intracellular fluid) is generally a reducing environment.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.

Is AOD-9604 the same as human growth hormone?

No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.

Does AOD-9604 occur naturally?

The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.

Has AOD-9604 been approved as a medicine?

No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.

Network